Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Fresenius Kabi Oncology Ltd

    Fresenius Kabi Oncology Limited is a public company primarily operating in the field of Research & Development and manufacturing of world-class oncology drugs. The company striv

  • No Image
    Fulford India Ltd

    Fulford (India) Limited, is the subsidiary of Merck & Co. Inc., Whitehouse Station, N.J., USA. Merck knows as MSD across the world (except in the US and Canada), operates in Ind

  • No Image
    G S Pharmaceuticals Pvt Ltd

    G S Pharmaceuticals Pvt. Ltd. was established as a proprietorship concern during the year 1979 in Muzaffarnagar. In 1985, the firm was incorporated as Private Limited Company. M

  • No Image
    Geistlich Pharma India Pvt Ltd

    Geistlich Pharma, a Swiss manufacturer of medical products, has commenced Indian operations, by establishing Geistlich Pharma India, a wholly-owned subsidiary and the 10th globa